Every compounding pharmacy business plan we see has a revenue line that climbs smoothly from opening day. Real ones do not. They start slowly, jump when a few prescribers start sending regular work, then sit on a plateau for months before the next step up. If your financing and your working capital are built on the smooth line, the plateau is where you run short of cash.
This article walks through a compounding start up’s first twelve months of full operation. It is a model, not one pharmacy: the ramp, the product mix and the margins come from the dispensing reports of compounding start ups we have worked with, scaled to a 4,000 square foot pharmacy with a non sterile lab, a hazardous hood and a sterile suite, in a secondary location rather than prime retail. It also fills commercial prescriptions. The figures are rounded, but the shape, a slow start, a jump, a long plateau and a second step, is how these businesses actually grow.
If you are still at the budgeting stage, read our guide to what it costs to build a compounding pharmacy in Canada first. This article picks up the day the doors open.
Before month one: the part the plan leaves out
In the builds behind this model, more than a year passed between signing the lease and filling the first prescription. A free fixturing period covered the first few months. After that, rent and common area costs, about $6,500 to $7,500 a month on a 4,000 square foot unit in a secondary location, ran for most of a year before revenue came in, along with insurance, software support, utilities and loan interest.
The sales that come in during the first few weeks are small. The model starts once regular operation begins, so month one below is the first full month of steady filling.
The lesson for any plan: the pre opening period is a cost line, not a footnote. Put it in the budget with a realistic date for first revenue, and then add three months.
The first twelve months
| Month | Prescriptions billed | Revenue | Gross profit | Gross margin |
|---|---|---|---|---|
| 1 | about 120 | $17,000 | $9,000 | 53% |
| 2 | about 190 | $28,000 | $15,000 | 54% |
| 3 | about 240 | $41,000 | $20,000 | 49% |
| 4 | about 380 | $70,000 | $39,000 | 56% |
| 5 | about 350 | $68,000 | $38,000 | 56% |
| 6 | about 360 | $64,000 | $35,000 | 55% |
| 7 | about 340 | $60,000 | $31,000 | 52% |
| 8 | about 370 | $63,000 | $34,000 | 54% |
| 9 | about 360 | $62,000 | $32,000 | 52% |
| 10 | about 410 | $70,000 | $37,000 | 53% |
| 11 | about 500 | $86,000 | $43,000 | 50% |
| 12 | about 520 | $95,000 | $45,000 | 47% |
| Year | about 4,100 | about $725,000 | about $380,000 | about 52% |
Three things stand out.
Month four was a jump, not a trend. Revenue went from $41,000 to $70,000 in one month. That kind of step almost always means a small number of prescribers began sending regular work. In data like this, the top compound, typically a multi ingredient pain cream, often appears in same day pairs, a pattern that points to a few referring clinics rather than broad community demand.
Months five to ten were flat. For six months revenue sat between $60,000 and $70,000. Nothing was wrong with the pharmacy. The first wave of prescribers was fully engaged and the next wave had not arrived. This is the plateau that business plans leave out, and it is where cash runs short if the plan assumed straight line growth.
Months eleven and twelve stepped up again, to $86,000 and $95,000. Early in the second year the pharmacy is running at more than $80,000 a month.
What carried the gross profit
Compounded preparations were about 70 percent of revenue and close to 90 percent of gross profit, at a gross margin of about 65 percent. Commercial prescriptions were about a quarter of revenue but well under 10 percent of gross profit, at about 15 percent margin.
By category, the compounding gross profit broke down roughly like this:
| Category | Share of total gross profit | Gross margin |
|---|---|---|
| Topical pain creams | about 35% | about 55% |
| Hormone capsules and creams | about 20% | about 80% |
| Erectile dysfunction compounds | about 9% | about 85% |
| Testosterone injections and creams | about 8% | about 75% |
| Other dermatology and topicals | about 8% | varies |
| Oral liquids and paediatric suspensions | about 7% | about 70% |
| Other capsules, including low dose naltrexone | about 4% | varies |
| Commercial prescriptions | about 7% | about 15% |
Two numbers are worth remembering. The average compounded prescription brings in about $165 in revenue and roughly $90 to $110 in gross profit, depending on how you count. The single largest formula, usually a pain cream, can account for about 15 percent of all sales and a similar share of gross profit. One formula, written mostly by a handful of prescribers, is carrying about one dollar in seven of the business.
We cover margins by product type in more depth in a separate article. For a business plan the point is simple: model gross margin by category, because the blend moves as the mix moves.
Where the growth came from
Start up dispensing data typically shows four distinct sources of volume, and a plan should account for each.
Referring clinics. The month four jump and the repeated same day pairs of the top pain cream point to a small number of clinics sending regular work. A single prescriber group can send several hundred fills in a year, mostly hormones and specialty pain creams.
Commercial prescriptions from the same prescribers. Intravenous iron and injectable products tend to grow fastest in the second half of the year, which usually means a prescriber who trusts the pharmacy with compounds starts sending other work too.
Pharmacist services. Minor ailment assessments add a small but steady line, a few dozen in the year.
Odd jobs. A few veterinary compounds and some sales of IV supplies to a clinic. Small, but they show the pharmacy saying yes to work other pharmacies turned away.
Why the margin fell as sales grew
Look at the gross margin column again. It was 56 percent in month four and 47 percent in month twelve, while revenue grew by about a third. The compounds did not get less profitable. Their margin held between 60 and 70 percent every month.
What changed was the mix. Commercial prescriptions grew from about 10 percent of revenue in month four to about a third in month twelve, led by intravenous iron infusions and GLP 1 pens. Those products have high drug costs and thin margins, often $40 to $75 of gross profit on a several hundred dollar claim. They bring in revenue and, very likely, deepen relationships with the prescribers who also write compounds. But every commercial dollar dilutes the blended margin.
A buyer or lender who sees only the blended number will think the pharmacy is getting worse. A plan that reports compounding and commercial separately shows what is actually happening.
Payer mix: not as cash heavy as people assume
Roughly 30 to 35 percent of first year revenue was paid entirely by patients, with no plan on the claim. Those cash claims carried a gross margin of about 60 percent and no write downs.
The rest had a private insurer or public plan on the claim. The largest private adjudicators each carried between 5 and 25 percent of revenue. Once insured volume built up, plan write downs, the difference between what the pharmacy charged and what the plans accepted, ran at 5 to 8 percent of revenue each month.
For a business plan this matters in two ways. First, do not assume compounding is a cash business with no reimbursement risk. Most of it is billed to insurers who can cap or decline. Second, the cash share is a strength in a sale. It is revenue that does not depend on any formulary.
Is it profitable?
Dispensing reports show revenue and gross profit, not wages or rent, so a model like this cannot give an exact first year profit. But the arithmetic is not hard. About $380,000 of gross profit has to pay at least one full time pharmacist, a technician or assistant, rent of about $80,000 to $90,000 a year for 4,000 square feet in a secondary location, software, insurance, supplies, utilities and certification costs. On a lean team, that is close to break even in year one. If the second year continues at the month twelve run rate, it is a profitable business.
That is a normal outcome for a compounding start up, and it is better than many. It is also why the pre opening period matters so much. A pharmacy that is roughly break even in year one cannot pay back a year or more of pre opening rent and interest out of operating cash. That money has to be in the plan as capital from day one.
Building a business plan that survives contact with reality
Based on the start ups we have worked with, here is what a compounding pharmacy business plan should contain.
A dated pre opening budget. Lease, fixturing period, construction, certification, licensing and a realistic first revenue date, with rent and wages running from the date they actually start.
A stepped ramp, not a curve. Model a slow start, a jump when your first prescribers commit, and a plateau of six months or more before the next step. Your working capital should carry you through the plateau.
Named prescribers. Before you sign a lease, know which prescribers will send work in the first six months and roughly how much. If you cannot name them, your month four jump has no foundation.
Margins by category. Topical pain, hormones, men’s health, paediatric, dermatology, sterile and commercial each behave differently. Model them separately.
Payer mix and write downs. Assume most compounds are billed to an insurer, and budget for write downs.
A concentration check. If one formula or one prescriber will be more than 15 percent of sales, say so and plan for what happens if it changes.
Six to twelve months of working capital. Six for a non sterile lab added to an operating pharmacy. Twelve for a standalone build with a sterile suite.
Lenders will test every one of these. A plan that already answers them gets financed faster and on better terms. Our article on how Canadian banks evaluate pharmacy financing covers what credit teams look for.
How we help
We are pharmacists who have built and sold our own pharmacies, and we have modelled compounding businesses from a single lab to a full sterile facility. We build business plans and ramp models from real dispensing data rather than industry averages, and we help owners line up prescribers, financing and the build itself.
If you are planning a compounding pharmacy, see our guide to building a pharmacy in Canada or contact us to book a consultation.